PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8461630

Cefotaxime desensitization.

G Papakonstantinou·J R Bogner·F Hofmeister·R Hehlmann
View original source ↗Export metadata ↓

Abstract

We report the successful desensitization to cefotaxime in a patient with severe lumbar osteomyelitis of unknown bacteriology and hypersensitivity to the drug. Desensitization was carried out because of the unknown bacteriology, the favorable response to cefotaxime at that time, and hypersensitivity to other antibiotics. On the first day the patient received 1 mg cefotaxime intravenously. The dose was increased for 13 successive days to 4 g cefotaxime intravenously per day. No allergic reaction occurred during desensitization or within 4 weeks of observation under this therapy. Patients with severe infections of unknown bacteriology might benefit from desensitization if therapy with a second-choice antibiotic is impossible.

Explore related subjects

CefotaximeDesensitization, ImmunologicDrug EruptionsDrug Therapy, CombinationFosfomycinHumansLumbar VertebraeMaleMiddle AgedPruritusSpondylitisCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G Papakonstantinou, J R Bogner, F Hofmeister, R Hehlmann. 1993. Cefotaxime desensitization.. https://doi.org/10.1007/bf00180000

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Serotype distribution and antimicrobial susceptibility of S. pneumoniae causing invasive disease in Thai children younger than 5 years old, 2000-2005.

In order to predict the potential benefit of pneumococcal conjugate vaccines (PCV), we evaluated the serotype coverage of the 7-, 9-, 11- and 13-valent PCV over the isolates causing invasive pneumococcal disease (IPD) in Thai children. One hundred and fifteen Streptococcus pneumoniae isolates from sterile sites in children younger than 5 years old between 2000 and 2005 were serotyped. The coverages of 7-, 9-, 11-, and 13-valent PCV were 69%, 73.8%, 73.8% and 85.7% in children younger than 2 years, and 73.9%, 77.4%, 77.4% and 87.8% in children younger than 5 years of age, respectively. 69.6% and 22.6% of the isolates were non-susceptible to penicillin and cefotaxime. 7-valent PCV covered 89% and 100% of penicillin and cefotaxime non-susceptible isolates.

Cefotaxime↗
PubMed2006

A nosocomial outbreak of Escherichia coli producing CTX-M-15 and OXA-30 beta-lactamase.

During a survey of the prevalent subtypes of extended-spectrum beta -lactamases in a university hospital in Korea, a nosocomial outbreak of Escherichia coli producing CTX-M-15 and OXA-30 beta -lactamases was detected. The outbreak comprised various infections, including bloodstream infections and colonization, and persisted for several months in various areas of the hospital.

Cefotaxime↗